This was the stock's second consecutive day of gains.

DexCom overview and recent share performance DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last ...

The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future. A ...

In three weeks, the ribbon will be cut on Connacht Rugby's new and improved Dexcom Stadium, completing the three-year, €40m ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical ...

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

As the year comes to a close, it's time to look back at the numerous innovations across the diabetes technology industry in ...

Significant changes at Johnson & Johnson were among the most-read medtech news on MassDevice over the past year.

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit.

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on ...

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Dec. 24, 2025 ...

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit.